To date, according to the latest American Thyroid Association (ATA) [2] and to the European Thyroid Association (ETA) guidelines [3], Tg remains the sole blood thyroid prognostic biomarker to assess recurrence or persistence and to monitor patients with differentiated thyroid carcinoma (DTC) who underwent total thyroidectomy and 131I radioiodine treatment for the ablation of residual thyroid tissue [4]. This evidence concerns the gene TG and differentiated thyroid carcinoma.